Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cumulative dose

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    780 result(s) found for: Cumulative dose. Displaying page 39 of 39.
    «« First « Previous 31  32  33  34  35  36  37  38  39 
    EudraCT Number: 2014-000722-38 Sponsor Protocol Number: 1203-GITCG Start Date*: 2015-05-25
    Sponsor Name:European Organisation for Research and Treatment of Cancer
    Full Title: INtegratioN of trastuzumab, with or without pertuzumab, into periOperatiVe chemotherApy of HER-2 posiTIve stOmach caNcer: the INNOVATION-TRIAL
    Medical condition: HER-2 positive, resectable gastric cancer
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066896 HER2 positive gastric cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) DE (Completed) BE (Completed) NO (Completed) PT (Completed) GB (GB - no longer in EU/EEA) ES (Completed) NL (Completed) FR (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-001192-39 Sponsor Protocol Number: P11-1 Start Date*: 2012-01-26
    Sponsor Name:Dendreon Corporation
    Full Title: AN OPEN-LABEL STUDY OF SIPULEUCEL-T IN EUROPEAN MEN WITH METASTATIC, CASTRATE RESISTANT PROSTATE CANCER
    Medical condition: metastatic castrate resistant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036910 Prostate cancer NOS LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066489 Progression of prostate cancer LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036916 Prostate cancer stage D LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: AT (Completed) GB (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2013-004054-21 Sponsor Protocol Number: CC-5013-DLC-002 Start Date*: 2014-09-26
    Sponsor Name:Celgene Corporation
    Full Title: Phase 3 Randomized, Double-Blind, Placebo Controlled, Multicenter Study to Compare the Efficacy and Safety of Lenalidomide (CC-5013) Plus R-CHOP Chemotherapy (R2-CHOP) Versus Placebo Plus R-CHOP Ch...
    Medical condition: Previously untreated, activated B-cell (ABC) type diffuse large B-cell lymphoma (DLBCL).
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10012859 Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) stage II LLT
    17.0 100000004864 10012855 Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) LLT
    17.0 100000004864 10012860 Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) stage III LLT
    17.0 100000004864 10012861 Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) IE (Completed) CZ (Completed) IT (Completed) PT (Completed) BE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2016-000401-36 Sponsor Protocol Number: DSC/14/2357/48 Start Date*: 2017-03-07
    Sponsor Name:ITALFARMACO S.p.A.
    Full Title: Randomised, double blind, placebo controlled, multicentre study to evaluate the efficacy and safety of givinostat in ambulant patients with Duchenne Muscular Dystrophy.
    Medical condition: Duchenne Muscular Dystrophy (DMD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    Population Age: Children, Adolescents, Under 18 Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) DE (Completed) NL (Completed) IT (Completed) ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-003993-30 Sponsor Protocol Number: IDP-121-1 Start Date*: 2022-07-01
    Sponsor Name:IDP Discovery Pharma S.L.
    Full Title: A phase 1/2 multicenter, open-label, dose-escalation study of IDP-121 in patients with relapsed/refractory hematologic malignancies
    Medical condition: Chronic lymphocytic leukemia (CLL) Diffuse large B cell lymphoma not otherwise specified (DLBCL-NOS) High-grade B cell lymphoma with double or triple hit rearrangement (HGBL-DH/TH) High-grade B cel...
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10008976 Chronic lymphocytic leukemia LLT
    21.0 100000004864 10028228 Multiple myeloma LLT
    20.0 100000004851 10020068 High grade B-cell lymphomas Burkitt-like lymphoma HLT
    21.0 100000004864 10012820 Diffuse large B-cell lymphoma NOS LLT
    21.1 100000004864 10020069 High grade B-cell lymphoma Burkitt-like lymphoma NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-000694-23 Sponsor Protocol Number: PCYC-1112-CA Start Date*: 2012-08-08
    Sponsor Name:Pharmacyclics LLC an Abbvie Company
    Full Title: A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor Ibrutinib versus Ofatumumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia...
    Medical condition: relapsed or refractory CLL/SLL
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10060671 B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IE (Completed) PL (Completed) ES (Completed) IT (Completed) AT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2012-001221-27 Sponsor Protocol Number: R727-CL-1119 Start Date*: 2013-03-20
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study to Evaluate the Efficacy and Safety of REGN727/SAR236553 in Patients with Primary Hypercholesterolemia Who are Intolerant to Statins
    Medical condition: Patients with primary hypercholesterolemia and moderate, high or very high cardiovascular (CV) risk who are intolerant to statins
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10020603 Hypercholesterolaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) IT (Completed) GB (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2009-015987-32 Sponsor Protocol Number: AV-951-09-902 Start Date*: 2010-04-02
    Sponsor Name:AVEO Pharmaceuticals, Inc.
    Full Title: An Extension Treatment Protocol for Subjects who have Participated in a Phase 3 Study of Tivozanib vs. Sorafenib in Renal Cell Carcinoma (Protocol AV-951-09-301)
    Medical condition: Advanced Renal Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    12.0 10050513 Metastatic renal cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) IT (Completed) CZ (Completed) HU (Completed) PL (Completed) BG (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-002482-19 Sponsor Protocol Number: 13EU/FSH01 Start Date*: 2013-12-12
    Sponsor Name:IBSA Institut Biochimique S.A.
    Full Title: Randomised clinical trial comparing highly purified FSH formulation (Fostimon®) and recombinant FSH (Gonal-F®) in GnRH-antagonist controlled ovarian hyperstimulation cycles.
    Medical condition: female infertility
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004872 10016398 Female infertility LLT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Completed) GB (Completed) ES (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2006-002576-18 Sponsor Protocol Number: A4061027 Start Date*: 2006-11-24
    Sponsor Name:Pfizer Ltd.
    Full Title: A PHASE 2 STUDY OF THE ANTI-ANGIOGENESIS AGENT AG-013736 IN PATIENTS METASTATIC OR UNRESECTABLE LOCALLY-ADVANCED THYROID CANCER REFRACTORY TO, OR NOT SUITABLE CANDIDATES FOR 131I TREATMENT
    Medical condition: Treatment of patients with 131I-refractory metastatic or unresectable locally-advanced papillary, follicular, or Hurthle-cell thyroid cancer who are also refractory to, or intolerant of, or have cl...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10055107 Thyroid cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2017-004830-28 Sponsor Protocol Number: CPKC412A2218 Start Date*: 2018-11-02
    Sponsor Name:Novartis Pharma AG
    Full Title: A Phase II, open-label, single arm study to evaluate the safety, efficacy, and pharmacokinetics of twice daily midostaurin (PKC412) combined with standard chemotherapy and as a single agent post-co...
    Medical condition: untreated FLT3-mutated acute myeloid leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000886 Acute myeloid leukemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) SI (Trial now transitioned) AT (Trial now transitioned) PL (Trial now transitioned) DE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-000195-34 Sponsor Protocol Number: MO25616 Start Date*: 2011-06-21
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A single arm, open-label, phase II, multicentre study to assess the safety of vismodegib (GDC-0449) in patients with locally advanced or metastatic basal cell carcinoma (BCC).
    Medical condition: Locally advanced or metastatic basal cell carcinoma (BCC)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10004146 Basal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) AT (Completed) DE (Completed) BG (Completed) GB (Completed) BE (Completed) IT (Completed) ES (Completed) NL (Completed) SI (Completed) DK (Completed) HU (Completed) CZ (Completed) GR (Completed) SK (Completed) IE (Completed) PT (Completed) PL (Completed) NO (Completed) LT (Completed) FI (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2017-002056-86 Sponsor Protocol Number: AIO-STO-0117 Start Date*: 2017-12-20
    Sponsor Name:AIO-Studien-gGmbH
    Full Title: A multicenter open-label phase II trial to evaluate Nivolumab and Ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer
    Medical condition: advanced esophageal squamous cell cancer
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062878 Gastrooesophageal cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055102 Oesophageal cancer metastatic PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015362 Esophageal cancer LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030151 Oesophageal cancer LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015363 Esophageal cancer NOS LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030152 Oesophageal cancer NOS LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10056267 Gastroesophageal cancer LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062478 Esophageal cancer metastatic LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-001729-26 Sponsor Protocol Number: CC-5013-MM-026 Start Date*: 2014-03-25
    Sponsor Name:Celgene Corporation
    Full Title: Phase 3b, Randomized Trial of Revlimid® (Lenalidomide) Versus Placebo Maintenance Therapy Following Melphalan Prednisone Velcade® (Bortezomib) Induction Therapy in Newly Diagnosed Multiple Myeloma
    Medical condition: Newly diagnosed multiple myeloma (NDMM)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) IT (Completed) FR (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2020-005760-57 Sponsor Protocol Number: CA42750 Start Date*: 2021-08-27
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OBINUTUZUMAB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
    Medical condition: Systemic Lupus Erythematosus (SLE)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) IT (Trial now transitioned) CZ (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-002781-31 Sponsor Protocol Number: PQBirch301 Start Date*: 2017-02-16
    Sponsor Name:Allergy Therapeutics (UK) Ltd
    Full Title: A multi-centre, double-blind, randomised, placebo-controlled, parallel-group study to evaluate the efficacy and safety of Birch Modified Allergen Tyrosine adsorbed + MPL in the prevention of season...
    Medical condition: Seasonal allergic rhinoconjunctivitis due to birch pollen
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000014962 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) SE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-004401-17 Sponsor Protocol Number: 204862 Start Date*: 2018-04-19
    Sponsor Name:ViiV Healthcare UK Limited
    Full Title: A Phase III, randomized, multicenter, parallel-group, non-inferiority study evaluating the efficacy, safety, and tolerability of switching to dolutegravir plus lamivudine in HIV-1 infected adults w...
    Medical condition: Human Immunodeficiency Virus-1 infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) ES (Completed) BE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2021-002864-36 Sponsor Protocol Number: PKRPC001 Start Date*: 2021-11-04
    Sponsor Name:Priothera S.A.S.
    Full Title: A prospective randomized, double-blind, placebo-controlled, multi-center phase IIb study to evaluate the efficacy and safety of mocravimod in acute myeloid leukemia (AML) patients undergoing alloge...
    Medical condition: Patients undergoing allogeneic hematopoietic stem cell transplant (HSCT) for acute myeloid leukemia (AML)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021428 - Immune system disorders 10018651 Graft versus host disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing) DE (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-004157-28 Sponsor Protocol Number: M10-223 Start Date*: 2008-06-23
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulce...
    Medical condition: Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10017947 - Gastrointestinal disorders 10009900 Colitis ulcerative PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) DE (Completed) HU (Completed) AT (Completed) SK (Completed) CZ (Completed) FR (Completed) IT (Completed) NL (Completed) PT (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2007-002693-66 Sponsor Protocol Number: 0822-018 Start Date*: 2007-11-13
    Sponsor Name:MERCK SHARP & DOHME CORP.
    Full Title: A Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of MK-0822 to Reduce the Risk of Fracture in Osteoporotic Postmenopausal Women Treated With Vitamin D an...
    Medical condition: Postmenopausal Osteoporosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10031285 Osteoporosis postmenopausal PT
    Population Age: Elderly Gender: Female
    Trial protocol: LT (Completed) DK (Completed) CZ (Prematurely Ended) PL (Prematurely Ended) GB (Prematurely Ended) DE (Completed) FR (Prematurely Ended) BE (Prematurely Ended) LV (Completed) EE (Completed) IT (Completed) ES (Completed) BG (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 31  32  33  34  35  36  37  38  39 
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 25 01:33:25 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA